Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participated in the lead-in study RVT-101-2001.~Exclusion Criteria:~* Any clinically relevant concomitant disease, which, in the opinion of the Investigator, makes the subject unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- RVT-101 35 mg (Type: EXPERIMENTAL): RVT-101 35 mg once daily
- RVT-101 70 mg (Type: EXPERIMENTAL): RVT-101 70 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).